Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options.
Margaretha A SkowronMara KotthoffFelix BremmerKatja RuhnkeFatma ParmaksizAnnika RichterStefan KüfferKirsten Reuter-JessenStella PaulsAnja StefanskiPhilipp StröbelKai StühlerDaniel NettersheimPublished in: Molecular medicine (Cambridge, Mass.) (2023)
In summary, this study offers a novel CLDN6-ADC to target GCT. Additionally, this study presents novel pharmacological inhibitors blocking FGF, VGF, PDGF, mTOR, CHEK1, AURKA, or PARP signaling for the treatment of (refractory) YST patients. Finally, this study shed light on the mechanisms of therapy resistance in YST.